Jaguar Health is an American commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for gastrointestinal (GI) distress, specifically chronic, debilitating diarrhea. It was incorporated in 2013 and is headquartered in San Francisco, California.
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential
Jaguar Health news
10.05.2022
Jaguar Health's GAAP loss for 3 months of 2022 was $18.164 million, up 51.3% from $12.009 million in the prior year. Revenue increased 2.11 times to $2.625 million from $1.241 million a year earlier.
Source: 
jaguarhealth.gcs-web.com
jaguarhealth.gcs-web.com
14.03.2022
Jaguar Health's GAAP loss for 2021 was $52.6 million, up 55.6% from $33.809 million the previous year. Revenue declined 2.2 times to $4.335 million from $9.385 million a year earlier.
Source: jaguarhealth.gcs-web.com
jaguarhealth.gcs-web.com
22.12.2021
Jaguar Health has received conditional FDA approval for the sale of Canalevia-CA1. The drug is designed to treat diarrhea in dogs caused by chemotherapy. Canalevia-CA1 was the first and only drug of its kind approved by the FDA.
Source: jaguarhealth.gcs-web.com
jaguarhealth.gcs-web.com
General information
| Company name | Jaguar Health |
|---|---|
| Tags | #biotechnology, #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 200 Pine Street Suite 400 San Francisco, CA 94104 United States |
| Mailing address | 200 Pine Street Suite 400 San Francisco, CA 94104 United States |
| Website | jaguarhealth.gcs-web.com |
English (US) 